| Main | | Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. | | Register: | EUCTR | | Last refreshed on: | 17 August 2015 | | Main ID: | EUCTR2010-023343-16-BE | | Date of registration: | 13/12/2010 | | Prospective Registration: | Yes | | Primary sponsor: | | | Public title: | An open-label study for the safety and efficacy of pomalidomide in refractory or refractory/relapsed multiple myeloma subjects | | Scientific title: | Open-label, multi-center, single-arm study for the safety and efficacy of pomalidomide (CC-4047) monotherapy for subjects with refractory or relapsed and refractory multiple myeloma: a companion study for clinical trial CC-4047-MM-003 - companion study for clinical trial CC-4047-MM-003 | | Date of first enrolment: | 31/03/2011 | | Target sample size: | 85 | | Recruitment status: | Not Recruiting | | URL: | https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-023343-16 | | Study type: | Interventional clinical trial of medicinal product | | Study design: | Controlled: no Randomised: no Open: no Single blind: no Double blind: no Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: no Other: no Number of treatment arms in the trial: 1 | | Phase: | | | Countries of recruitment | | Australia | Belgium | Canada | Czech Republic | Denmark | Germany | Greece | Italy | | Netherlands | Russian Federation | Spain | Sweden | Switzerland | United Kingdom | | Contacts | | Name: | ClinicalTrialDisclosure | | Address: | 9225 Indian Creek Parkway, Suite 900 66210 Kansas United States | | Telephone: | +1-888-260-1599 | | Email: | ClinicalTrialDisclosure@celgene.com | | Affiliation: | Celgene Corporation | | | Name: | ClinicalTrialDisclosure | | Address: | 9225 Indian Creek Parkway, Suite 900 66210 Kansas United States | | Telephone: | +1-888-260-1599 | | Email: | ClinicalTrialDisclosure@celgene.com | | Affiliation: | Celgene Corporation | | | Key inclusion & exclusion criteria | | Inclusion criteria: 1.Subjects with refractory or relapsed and refractory multiple myeloma who were enrolled in Study CC-4047-MM-003 and discontinued study therapy with dexamethasone alone (Treatment Arm B) after at least starting the second cycle of dexamethasone treatment and due to development of documented disease progression according to the IMWG criteria and as decided by an IRAC. 2.Must be = 18 years at the time of signing the informed consent form. 3.The subject must understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted. The only exception is if a skeletal survey was performed within 90 days prior to the start of Cycle 1, then a new survey will not berequired. 4.Must be able to adhere to the study visit schedule and other protocol requirements.5.Subjects must have documented diagnosis of multiple myeloma and have measurable disease (serum M-protein = 0.5g/dL or urine M-protein= 200 mg/24 hours). 6.Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2. 7. Females of childbearing potential (FCBP†) must agree to utilize two reliable forms of contraception simultaneously or practice true abstinence [when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post ovulation methods) and withdrawal are not acceptable methods of contraception]from heterosexual contact for at least 28 days before starting study drug, while participating in the study (including dose interruptions), and for at least 28 days after study treatment discontinuation and must agree to regular pregnancy testing during this timeframe.8.Females must agree to abstain from breastfeeding during study participation and 28 days after study discontinuation. 9. Males must agree to either use a latex condom during any sexual contact with FCBP or practice true abstinence [when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception] while participating in the study and for 28 days following discontinuation from this study, even if he has undergone a successful vasectomy.10.Males must also agree to refrain from donating semen or sperm whileon pomalidomide and for 28 days after discontinuation from this study treatment. 11.All subjects must agree to refrain from donating blood while on study drug and for 28 days after discontinuation from this study treatment. 12.All subjects must agree not to share study medication. Are the trial subjects under 18? noNumber of subjects for this age range: 0F.1.2 Adults (18-64 years) yesF.1.2.1 Number of subjects for this age range 42F.1.3 Elderly (>=65 years) yesF.1.3.1 Number of subjects for this age range 28 Exclusion criteria: 1.Subjects with multiple myeloma who were not treated as a part of Study CC-4047-MM-003 (Arm B). 2.Subjects who received anti-myeloma, or anti-cancer therapies within the last 14 days of wash-out period before initiation of study treatment.3.Subjects who discontinued CC-4047-MM-003 study =120 days.4.Subjects who initiate another anti-myeloma therapy from the time of disease progression on study CC-4047-MM-003 to the time of treatment initiation in the companion study.5.Any of the following laboratory abnormalities:•Absolute neutrophil count (ANC) < 1,000/µL. •Platelet count < 75,000/µL for subjects in whom < 50% of bone marrow nucleated cells are plasma cells; or a platelet count < 30,000/µLfor subjects in whom = 50% of bone marrow nucleated cells are plasma cells•Creatinine Clearance < 45 mL/min according to Cockcroft-Gault formula (if creatinine clearance calculated from the 24-hour urine sample is >=45 mL/min, patient will qualify for the trial)•Corrected serum calcium > 14 mg/dL (> 3.5 mmol/L); •Hemoglobin < 8 g/dL (< 4.9 mmol/L; prior RBC transfusion or recombinant human erythropoietin use is permitted)•Serum SGOT/AST or SGPT/ALT > 3.0 x upper limit of normal (ULN)•Serum total bilirubin > 2.0 mg/dL (34.2 µmol/L); or > 3.0 x ULN for subjects with hereditary benign hyperbilirubinaemia6.Prior history of malignancies, other than MM, unless the subject has been free of the disease for = 5 years. Exceptions include the following:•Basal or Squamous cell carcinoma of the skin•Carcinoma in situ of the cervix or breast•Incidental histologic finding of prostate cancer (TNM stage of T1a or T1b)7.Hypersensitivity to thalidomide or lenalidomide. (This includes = Grade 3 rash during prior thalidomide or lenalidomide therapy).8.Peripheral neuropathy = Grade 2. 9.Subjects who received an allogeneic bone marrow or allogeneic peripheral blood stem cell transplant less than 12 months prior to initiation of study treatment and who have not discontinued immunosuppressive treatment for at least 4 weeks prior to initiation of study treatment and are currently dependent on such treatment.10.Subjects who are planning for or who are eligible for stem cell transplant.11.Subjects with any one of the following: •Congestive heart failure (NY Heart Association Class III or IV)•Myocardial infarction within 12 months prior to starting study treatment•Unstable or poorly controlled angina pectoris, including Prinzmetal variant angina pectoris12.Subjects who received any of the following within the last 14 days of initiation of study treatment:•Plasmapheresis•Major surgery (kyphoplasty is not considered major surgery)•Radiation therapy13.Use of any investigational agents within 28 days or 5 half lives (whichever is longer) of treatment. 14.Subjects with chronic conditions such as rheumatoid arthritis, multiple sclerosis and lupus, which likely need additional steroid or immunosuppressive treatments in addition to the study treatment.15.Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study. 16.Incidence of gastrointestinal disease that may significantly alter the absorption of pomalidomide. 17.Subjects unable or unwilling to undergo antithrombotic prophylactic treatment.18.Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the i Age minimum: Age maximum: Gender: Female: yesMale: yes | | Health Condition(s) or Problem(s) studied | | Refractory or relapsed and refractory multiple myeloma MedDRA version: 16.1 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864 | | Therapeutic area: Diseases [C] - Cancer [C04] | | Intervention(s) | | Trade Name: Imnovid 4 mg hard capsulesPharmaceutical Form: Capsule, hardINN or Proposed INN: PomalidomideCAS Number: 19171-19-8Current Sponsor code: CC-4047Concentration unit: mg milligram(s)Concentration type: equalConcentration number: 4-Trade Name: Imnovid 3 mg hard capsulesPharmaceutical Form: Capsule, hardINN or Proposed INN: PomalidomideCAS Number: 19171-19-8Current Sponsor code: CC-4047Concentration unit: mg milligram(s)Concentration type: equalConcentration number: 3-Trade Name: Imnovid 2 mg hard capsulesPharmaceutical Form: Capsule, hardINN or Proposed INN: PomalidomideCAS Number: 19171-19-8Current Sponsor code: CC-4047Concentration unit: mg milligram(s)Concentration type: equalConcentration number: 2-Trade Name: Imnovid 1 mg hard capsulesPharmaceutical Form: Capsule, hardINN or Proposed INN: PomalidomideCAS Number: 19171-19-8Current Sponsor code: CC-4047Concentration unit: mg milligram(s)Concentration type: equalConcentration number: 1- | | Primary Outcome(s) | | Main Objective: To evaluate the efficacy of pomalidomide (CC-4047) monotherapy in subjects with refractory or relapsed and refractory multiple myeloma who discontinued from Treatment Arm B (dexamethasone alone) of Study CC-4047-MM-003 due to the development of documented disease progression during treatment. | | Primary end point(s): The primary endpoint is overall response rate (ORR) using the new International Myeloma Working Group Uniform (IMWG) response criteria. An analysis comparing the results of response assessments judged by the EMBT criteria (Blade, 1998) to those of the IMWG criteria will also be performed. | | Timepoint(s) of evaluation of this end point: Time to event | | Secondary Objective: To evaluate the safety of pomalidomide monotherapy in subjects with refractory or relapsed and refractory multiple myeloma who discontinued treatment after being treated in the dexamethasone alone arm (Treatment Arm B) in Study CC-4047-MM-003 due to the development of documented disease progression during treatment. | | Secondary Outcome(s) | | Timepoint(s) of evaluation of this end point: Time to event | | Secondary end point(s): • Safety (type, frequency, and severity of adverse events [AEs], and relationship of AEs to study drug)• Progression-free survival (PFS)• Time to progression (TTP)• Duration of response• Overall survival (OS) | | Secondary ID(s) | | CC-4047-MM-003/C | | Source(s) of Monetary Support | | Celgene Corporation | | Results | | Results available: | | Date Posted: | | Date Completed: | | URL: | | |
